Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar;18(3):322-30.
doi: 10.1007/s12094-015-1372-1. Epub 2015 Aug 11.

Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis

Q Lv  1 , L Gong  2 , T Zhang  1 , J Ye  1 , L Chai  3 , C Ni  4 , Y Mao  5
Affiliations
Review

Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis

Q Lv et al. Clin Transl Oncol. 2016 Mar.

Abstract

Objective: Metastatic breast cancer (MBC) remains the main cause of cancer-related death, and the clinical significance and prognostic role of circulating tumor cells (CTCs) in metastatic breast cancer are still controversial. Here, we conducted a meta-analysis to clarify the correlation between CTCs and the clinicopathological features and prognosis of MBC.

Methods: We performed a comprehensive search of Pubmed and the ISI Web of Science through December 2014. Only articles that focused on MBC patients and detected CTCs using the CellSearch system were included. The associations between CTCs and survival rate and clinicopathological parameters, including molecular pattern, metastatic region and treatment response, were evaluated.

Results: This meta-analysis included 24 studies (3701 MBC patients), 13 prospective studies and 11 retrospective studies. We found that CTCs were more frequently detected with HER2 + primary tumors (pooled RR = 0.73, 95 % CI = 0.63-0.84). Additionally, higher CTC numbers indicated a worse treatment response (RR = 0.56, 95 % CI = 0.40-0.79), poorer PFS (RR = 0.64, 95 % CI = 0.56-0.73) and poorer OS (RR = 0.69, 95 % CI = 0.64-0.75) in MBC patients.

Conclusion: Based on these results, we propose that HER2 positivity could be a significant risk factor for the presence of CTCs. Additionally, CTCs have a significant prognostic value for MBC patients. Therefore, CTCs should be continually monitored to guide the treatment of MBC patients, especially those with HER2 + primary tumors.

Keywords: Breast cancer; Circulating tumor cells; Her2; Meta-analysis; Prognosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. PLoS One. 2011 Jan 10;6(1):e15624 - PubMed
    1. Clin Breast Cancer. 2012 Oct;12(5):340-6 - PubMed
    1. Clin Chem. 2007 Mar;53(3):537-9 - PubMed
    1. Breast Cancer Res Treat. 2013 Jan;137(2):503-10 - PubMed
    1. J Oncol. 2010;2010:617421 - PubMed

LinkOut - more resources